The United Kingdom and the United States have hammered out a major bilateral deal that will preserve no duties on UK medicine products entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase expenditure on medicines through the National Health Service (NHS). This pledge secures that import taxes on these key products will be held at nothing for a timeframe of three years.
This agreement comes after previous threats to dramatically increase tariffs on patented pharmaceutical products, with increases mentioned up to double the cost.
"This arrangement with the Britain bolsters the global environment for new treatments and brings long-overdue balance to transatlantic medicine commerce," a release said.
Economic Importance
Pharmaceuticals constitute one of the Britain's most significant goods shipped to the America, which is easily the largest market for large British pharmaceutical firms.
Statistics show that in the one-year period leading up to the third quarter, the UK shipped medicines totaling £11.1bn to the US. This value made up 17.4% of all goods exports in that period.
"This deal secures work, increases funding and paves the way for the UK to become a international leader for life sciences," a minister commented.
Key British Pledges
The pact involves several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall public funding on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds were more than twenty percent.
Industry Background
The pact follows a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were heightened by arguments that US customers were charged significantly more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or abandoned, while substantial investments have been announced toward projects in the United States.
One official acknowledged that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.
